The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prospective, randomized, placebo-controlled phase 2b trial of SurVaxM plus adjuvant temozolomide in newly diagnosed glioblastoma (SURVIVE).
 
Manmeet Ahluwalia
Stock and Other Ownership Interests - doctible; Live AI; MedInnovate Advisors LLC; MimiVax; Modifi Bio; TriSalus Life Sciences
Consulting or Advisory Role - AlloVir; Apollomics; Autem Therapeutics; Bayer; Bugworks; Equillium; GT Medical Technologies; Incyte; Menarini Group; Modifi Bio; Pyramid Biosciences; Recordati; SERVIER; Sumitomo Dainippon Pharma Oncology; VBI Vaccines; Xoft
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst); Seagen (Inst)
Other Relationship - Idorsia (I); ResMed (I)
 
David Reardon
Stock and Other Ownership Interests - Anheart Therapeutics; Bionaut Labs
Honoraria - Advantagene; Agenus; Anheart Therapeutics; Avita Biomedical, Inc.; Bayer; Blue Rock Therapeutics; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CeCaVa; Chimeric Therapeutics; Deciphera; DelMar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Genentech/Roche; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kintara Therapeutics; KIYATEC; Medicenna; Merck; Merck KGaA; Monteris Medical; NEUVOGEN; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics; Sumitono Dainippon Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Vivacitas Oncology; Y-mAbs Therapeutics
Consulting or Advisory Role - Advantagene; Agenus; Agios; Anheart Therapeutics; Avita Biomedical; Bayer; Blue Rock Therapeutics; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CeCava; Chimeric Therapeutics; Deciphera; Delmar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Genentech/Roche; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kiyatec; Medicenna; Merck; Merck KGaA; NEUVOGEN; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics; Sumitomo Dainippon Pharma Oncology; Taiho Pharmaceutical; Vivacitas Oncology
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Asvattha Therapeutics (Inst); Celldex (Inst); EMD Serono (Inst); Enterome (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); InSightec (Inst); Merck (Inst); NeoTX (Inst); Novartis (Inst); Omniox
 
Nicholas Butowski
Employment - University of California, San Francisco
Stock and Other Ownership Interests - Cordance; Cordance
Consulting or Advisory Role - IN8Bio; Ipsen; Novartis; Plus Therapeutics
Research Funding - Amgen; Amgen (Inst); Bristol-Myers Squibb (Inst); Carthera; Five Prime Therapeutics; Medicenna; Merck; Oncoceutics (Inst); Tango Therapeutics
 
Robert Aiken
Stock and Other Ownership Interests - Johnson & Johnson/Janssen; Northwest Biotherapeutics
Consulting or Advisory Role - tactical
Research Funding - Abbott/AbbVie; Avila Therapeutics; Oncoceutics (Inst)
Expert Testimony - Tactical Therapeutics
Other Relationship - Imvax
 
David Peereboom
Honoraria - MJH Life Sciences; Novocure
Consulting or Advisory Role - Anheart Therapeutics; Neonc Technologies; Novocure; Orbus Therapeutics; SERVIER
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Curis (Inst); Genentech/Roche (Inst); MimiVax (Inst); Neonc Technologies (Inst); Novartis (Inst); Nuvation Bio (Inst); Ono Pharmaceutical (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Vigeo Therapeutics (Inst)
Travel, Accommodations, Expenses - Novocure
 
Vyshak Venur
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - MimiVax, LL; Ono Pharmaceutical
 
Ajay Abad
No Relationships to Disclose
 
Ahmed Belal
No Relationships to Disclose
 
Danielle Casucci
No Relationships to Disclose
 
Sheila Figel
No Relationships to Disclose
 
Yazmin Odia
Consulting or Advisory Role - Chimerix; Exelixis; GammaTile; Klick; Modifi Bio; PharPoint Research; SERVIER
Research Funding - Cantex (Inst); CarThera (Inst); Chimerix (Inst); cns pharmaceuticals (Inst); Exelixis (Inst); Merck (Inst); MimiVax, LL (Inst); Novocure (Inst); VBI Vaccines (Inst)
Travel, Accommodations, Expenses - Chimerix
 
Zhijian Chen
No Relationships to Disclose
 
Kaylyn Sinicrope
No Relationships to Disclose
 
John Boockvar
No Relationships to Disclose
 
Marissa Barbaro
No Relationships to Disclose
 
Andrew Brenner
No Relationships to Disclose
 
Brian Vaillant
No Relationships to Disclose
 
Robert Fenstermaker
No Relationships to Disclose
 
Michael Ciesielski
Employment - MimiVax
Leadership - MimiVax
Stock and Other Ownership Interests - MimiVax
Research Funding - MimiVax (Inst)
Patents, Royalties, Other Intellectual Property - Patent holder, SurVaxM
Travel, Accommodations, Expenses - MimiVax
 
Jing-Xin Qiu
No Relationships to Disclose